On May 7, 2024, G Iiekking, Chief Financial Officer of Usana Health Sciences Inc (NYSE:USNA), sold 5,198 shares of the company. The transaction was documented in a recent SEC Filing.
Usana Health Sciences Inc (NYSE:USNA) specializes in the development and manufacture of science-based nutritional and personal care products. The company’s range of products is distributed globally, primarily via direct selling channels.
Over the past year, the insider has sold a total of 5,198 shares and has not purchased any shares. This recent sale continues a trend observed over the past year, where there have been 26 insider sells and no insider buys.
On the date of the sale, shares of Usana Health Sciences Inc were priced at $44.76, resulting in a market cap of approximately $860.821 million. The company’s price-earnings ratio stands at 13.94, below both the industry median of 18.79 and the companys historical median.
According to the GF Value, which is an intrinsic value estimate from GuruFocus, Usana Health Sciences Inc is considered Modestly Undervalued with a GF Value of $59.42. This assessment is based on historical trading multiples, an adjustment factor from past returns and growth, and future business performance estimates.
The price-to-GF-Value ratio, at the time of the insider’s sale, was 0.75, suggesting that the stock might be undervalued.
This sale by the insider might be of interest to current and potential investors, providing insight into insider confidence and valuation perspectives at Usana Health Sciences Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
